What is the current size and annual growth rate of the mrna therapeutics market?
The mRNA therapeutics market size has grown steadily in recent years. It will grow from $34.76 billion in 2024 to $36.25 billion in 2025 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to increasing financial support for the creation of efficient pharmaceuticals and vaccines, the expansion of federal programs dedicated to advancing RNA-based medicines heightened awareness regarding rare genetic diseases, and a rise in the number of clinical trials.
The mRNA therapeutics market size is expected to see steady growth in the next few years. It will grow to $42.23 billion in 2029 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to the growing number of infectious diseases, the increasing number of patients visiting hospitals and clinics, expanding applications of mRNA therapeutics, growing demand for personalized and precision medicine, favorable regulatory environments, and accelerated approval pathways. Major trends in the forecast period include advancements in mRNA delivery technologies, rapid development and adaptation of mRNA vaccines, the emergence of self-amplifying mRNA (saRNA) platforms, the scalability and flexibility of mRNA manufacturing, and the development of novel mRNA modifications.
Get Your Free Sample of The Global mRNA Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17205&type=smp
Which industry factors have accelerated the mrna therapeutics market’s expansion?
The increased prevalence of long-lasting and communicable diseases is expected to propel the growth of the mRNA therapeutics market going forward. Long-lasting and communicable diseases are illnesses that persist for extended periods and can be transmitted between individuals, such as tuberculosis, HIV/AIDS, and hepatitis. The prevalence of long-lasting and communicable diseases is increasing due to increased global travel and inadequate healthcare infrastructure, which facilitate the spread and hinder the effective management of these illnesses. mRNA therapeutics are useful for long-lasting and communicable diseases by rapidly enabling the body to produce proteins that boost immune responses, leading to quicker development of vaccines and treatments. For instance, in October 2023, according to GOV.UK, a UK-based government website, in 2022, there were 94,397 people in England living with diagnosed HIV and receiving care, a 3% increase from the 91,368 individuals in 2021. Therefore, the increased prevalence of long-lasting and communicable diseases is driving the growth of the mRNA therapeutics market.
What are the primary segments of the mrna therapeutics market?
The mRNA therapeutics market covered in this report is segmented –
1) By Product: Vaccines, Drugs
2) By Application: Infectious Diseases, Oncology, Rare Genetic Diseases, Respiratory Diseases, Other Applications
3) By End Use: Hospitals And Clinics, Research Organizations, Other End Uses
Subsegments:
1) By Vaccines: Infectious Disease Vaccines, Cancer Vaccines, Other Therapeutic Vaccines
2) By Drugs: Oncology Drugs, Cardiovascular Drugs, Autoimmune Disease Drugs, Other mRNA-Based Drugs
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report
Which firms are leading the mrna therapeutics market?
Major companies operating in the mRNA therapeutics market are Pfizer Inc., Novartis AG, Sanofi AG, AstraZeneca plc, GlaxoSmithKline plc, Hoffmann-La Roche AG, Moderna Therapeutics Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Catalent Inc, Alnylam Pharmaceuticals Inc, Sarepta Therapeutics Inc, Arcturus Therapeutics Holdings Inc, CureVac N.V, Ethris GMBH, eTheRNA immunotherapies NV, In-Cell-Art S.A.S., Nutcracker Therapeutics Inc, SCM LifeScience Co Ltd, Suzhou Abogen Biosciences Co Ltd, Tiba Biotech LLC, CSPC Pharmaceutical Group, CRISPR Therapeutics AG
Which market trends are set to define the future of the mrna therapeutics market?
Major companies operating in the mRNA therapeutics market are focusing on developing innovative solutions, such as mRNA-based booster vaccines, to enhance immunity against evolving viral variants. An mRNA-based booster vaccine refers to a vaccine that uses messenger RNA (mRNA) technology to enhance and prolong immunity against a specific pathogen, often after the initial vaccination series. For instance, in June 2023, Gennova Biopharmaceuticals Ltd., an India-based pharmaceutical company, launched India’s first indigenous mRNA-based Omicron-specific booster vaccine called GEMCOVAC-OM to provide a variant-specific vaccine that can elicit desired immune responses against the Omicron variant of SARS-CoV-2. GEMCOVAC-OM is thermostable, does not require ultra-cold chain infrastructure, and can be administered without a needle injection using a needle-free device system, making it easy for last-mile deployment in India. In clinical studies, the vaccine generated significantly higher immune responses compared to other vaccines, demonstrating the need for variant-specific vaccines to elicit desired immune responses.
Which geographic trends are shaping the mrna therapeutics market, and which region has the highest market share?
North America was the largest region in the mRNA therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mRNA therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The mRNA Therapeutics Market Report 2025 Offer?
The mrna therapeutics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Messenger RNA (mRNA) therapeutics refers to a type of medical treatment that utilizes messenger RNA (mRNA) molecules to produce therapeutic proteins within the body. These therapeutics are used to prevent, treat, or cure diseases by directing cells to produce specific proteins that are needed for therapeutic effects.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17205
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
